Table 1.

Characteristics of included clinical trials

Author	Year of publication	Disease site	Disease stage	Treatment setting	Number of participants	Line of therapy	ICI used	Method used to measure DNA	Expected ctDNA response	Timing of second ctDNA collection
Anagnostou et al15	2019	Lung cancer	Metastatic NSCLC	Pallitative	19	First line	Nivolimab	TEC-Seq NGS	Undetectable	6
Cabel et al38	2017	Lung cancer, uveal melanoma and MSI-H CRC	Metastatic	Pallitative	10	First line	Mixed	Bidirectional pyrophosphorolysis-activated polymerization, droplet digital PCR or next-generation sequencing depending on the mutation type	Undetectable	8
Garassino et al39	2018	Lung cancer	Locally advanced unresectable or metastatic	Palliative	65	Third or more line	Durvalumab	ctDNA using Guardant360	Undetectable	6
Goldberg et al16	2018	Lung cancer	Metastatic NSCLC	Pallitative	28	First line	Mixed	Ultra-deep next-generation sequencing/error-suppressed deep sequencing method	50% reduction	6
Herbreteau et al40	2018	Melanoma	Locally advanced unresectable or metastatic	Palliative	53	First or second line	Nivolumab +- ipilimumab	Droplet digital PCR	Undetectable	16
Jin et al19	2020	Gastric cancer	Metastatic gastric cancer	Pallitative	40	Second or more line	Mixed/multiple	HiSeq4000 NGS platform (Illumina)	Undetectable	8
Kim et al22	2018	Gastric cancer	Metastatic	Palliative	23	Second or more line	Pembrolizumab	ctDNA using Guardant360	50% reduction	6
Lee et al41	2017	Melanoma	Metastatic	Palliative	40	First line	Pembrolizumab or nivolumab +- ipilimumab	Droplet digital PCR	Undetectable	12
Lee et al42	2020	Melanoma	Metastatic melanoma to brain	Pallitative	72	First line	Pembrolizumab or nivolumab +- ipilimumab	Droplet digital PCR	Undetectable	12
Giroux Leprieur et al21	2018	Lung cancer	Metastatic	Pallitative	15	Second or more line	Nivolumab	NGS	Undetectable	8
Marsavela et al43	2020	Melanoma	Metastatic	Palliative	32	First line	Variable	Droplet digital PCR	Undetectable	N/A
Marsavela et al18	2020	Melanoma	Metastatic	Palliative	15	Second or more line	Variable	Droplet digital PCR	Undetectable	12
Moding et al44	2020	Lung cancer	Locally advanced unresectable NSCLC	Consolidation ICIs following chemoradiation	15	Consolidation	Nivolumab	Gene panel sequencing by NGS	50% reduction	8
Pedersen et al45	2020	Melanoma	Locally advanced unresectable or Metastatic	Pallitative	16	First line	Pembrolizumab or nivolumab/ipilimumab	Droplet digital PCR	Undetectable	7
Raja et al20	2018	Lung cancer	Metastatic	Palliative	26	Second or more line	Durvalumab	ctDNA using Gaurdant360	Undetectable	6
Varaljai et al14	2020	Melanoma	Metastatic BRAF V600E positive	Palliative	18	First line	Pembrolizumab or nivolumab/ipilimumab	Droplet digital PCR	Decrease vs increase	10
Warburton et al17	2020	Melanoma	Metastatic	Palliative	38	First or second line	Pembrolizumab	Droplet digital PCR	Undetectable	16
Zheng et al46	2018	Urothelial cancer	Metastatic	Palliative	27	Second or more line	Durvalumab	ctDNA using Gaurdant360	Undetectable vs detectable	6

CRC, colorectal cancer; ICI, immune checkpoint inhibitor; MSI-H, microsatellite instability-high; NGS, next generation sequencing; NSCLC, non-small cell lung cancer.